Lesli Nall, PA
Medical · Henderson, KYNPI 1750621561
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,936 of the $6,702 with a category attached, or 88.6%. It is spread thinly across 36 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 356 payments — averaging $18.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Lilly USA, LLC$747
- Amgen$542
- Novo Nordisk$490
- Insulet Corporation$441
- AstraZeneca$355
- plus $3K from 30 others
What the payments were for
- Travel & lodging$69510%
- Food & beverage$5,93689%
- Education$711%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 24 | $1,153 |
| Lilly USA, LLC | 45 | $747 |
| Amgen | 40 | $542 |
| Novo Nordisk | 32 | $490 |
| Insulet Corporation | 19 | $441 |
| AstraZeneca(2 entities) | 22 | $355 |
| Boehringer Ingelheim | 21 | $352 |
| Dexcom, Inc. | 14 | $319 |
| Novartis | 22 | $257 |
| AbbVie | 14 | $255 |
| Sanofi-aventis U.S. LLC | 13 | $217 |
| Abbott | 12 | $212 |
| Corcept Therapeutics | 10 | $159 |
| Xeris Pharmaceuticals, Inc. | 9 | $152 |
| Radius Health, Inc. | 7 | $120 |
| Recordati_rare_diseases_inc. | 6 | $103 |
| Mannkind Corporation | 5 | $88 |
| Tandem Diabetes Care, Inc. | 4 | $81 |
| Teva Pharmaceuticals USA, Inc. | 4 | $76 |
| Nevro Corp. | 3 | $62 |
| Amarin Pharma, Inc. | 4 | $60 |
| Bayer | 3 | $52 |
| Neurocrine Biosciences, Inc. | 3 | $51 |
| Lundbeck LLC | 2 | $42 |
| Cequr Corporation | 1 | $40 |
| BETA Bionics, Inc. | 2 | $39 |
| GRT US Holding, Inc. | 2 | $34 |
| Kyowa Kirin, Inc. | 2 | $32 |
| Grifols USA, LLC | 2 | $32 |
| Zealand Pharma US, Inc. | 2 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Averitas Pharma Inc. | 1 | $20 |
| Endo Pharmaceuticals Inc. | 1 | $19 |
| Ascensia Diabetes Care US Inc. | 1 | $19 |
| Avvisto Therapeutics, LLC | 1 | $15 |
| Antares Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$296
- Omnipod$125
How this compares
$6,702 in reported general payments places this provider in the 90th percentile of 222 medical providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 366 | $414,967 |
| MounjaroTirzepatide | 310 | $350,444 |
| JardianceEmpagliflozin | 165 | $137,278 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 109 | $119,578 |
| TrulicityDulaglutide | 77 | $96,127 |
| FarxigaDapagliflozin Propanediol | 95 | $90,789 |
| Tresiba Flextouch U-200Insulin Degludec | 77 | $81,953 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 54 | $56,328 |
| Tresiba Flextouch U-100Insulin Degludec | 75 | $49,381 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 46 | $47,080 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 59 | $40,988 |
| Humalog Kwikpen U-200Insulin Lispro | 21 | $38,513 |
| Repatha SureclickEvolocumab | 45 | $37,771 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 39 | $33,990 |
| RybelsusSemaglutide | 22 | $33,982 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog, Insulin Lispro | $747 | $479,892462 claims |
| Novo NordiskOzempic, Rybelsus, Novolog, Fiasp | $490 | $475,687461 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $352 | $152,791176 claims |
| AstraZenecaFarxiga | $355 | $90,78995 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $217 | $56,32854 claims |
| AbbVieSynthroid | $255 | $14,564213 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCCycloset | $28 | $10,42915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 222 medical providers in Kentucky.
Other medical in Henderson
- Mikal BaileyPaducah$84K
- Kyle HeraldBowling Green$65K
- Chasity HesterLexington$16K
- Alexandra HuettLouisville$13K
- Danny ThackerFrankfort$11K
- Jessica FrizzellPaducah$10K
- Terry SmithHazard$10K
- Ashley HenegarGeorgetown$10K
- Rachel CrowleyPaducah$8K
- Allison ScottLexington$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.